Effect Of Sacubitril Valsartan On Cardiac Function And Myocardial Fibrosis In Chronic Heart Failure Patients With Reduced Ejection Fraction

Objective:To observe the effect of sacubitril valsartan on the cardiac function and myocardial fibrosis indexes of chronic heart failure Patients with reduced ejection fraction.Methods:The Patient suffered from heart failure with reduced ejection fraction was collected as research objects.Seventy-eight Patients were obtained from the De Partment of Cardiology of Qinghai Provincial Peo Ple’s Hos Pital from October 2019 to October 2020.The enrolled Patients were divided into case grou P(n=40)and control grou P(n=38).Collecting blood sam Ples from Patients before treatment and after 3 months of treatment,Plasma myocardial fibrosis indexes were measured by ELISA;Analyzing the general data of each grou P of Patients,such as myocardial fibrosis indexes,laboratory tests,cardiac color Do PPler ultrasound,NYHA grade,KCCQ score and so on.Results:(1)ComParing basic data of the two grouPs.There was no statistically difference in basic data(P>0.05).(2)After treatment in case grouP: sST2,TIMP-1,BNP,LVEF,LAD,LVEDD,LVESD,LVEDV,SPAP,KCCQ score,cardiothoracic ratio,NYHA grade,Heart rate,BMI,Cr,BUN,and HbA1c were im Proved com Pared with before treatment(P<0.05);MMP-9,E/A,SBP,DBP,eGFR,Hb,Plt,FBG,TC,TG,HDL-C,and LDL-C were no significant change.The difference was not statistically significant(P>0.05).(3)After treatment in control grou P: BNP,LVEF,LVEDD,LVEDV,SPAP,KCCQ score,NYHA grade,cardiothoracic ratio,DBP,e GFR,and Cr were im Proved com Pared with before treatment(P<0.05);sST2,TIMP-1,MMP-9,LAD,LVESD,E/A,SBP,Heart rate,BMI,Hb,Plt,BUN,FBG,TC,TG,HDL-C,LDL-C,and HbA1c did not change,and the difference was not statistically significant(P>0.05).(4)Com Paring in the case grou P and the control grou P: After treatment,sST2,TIMP-1,BNP,LVEF,LAD,LVEDD,LVESD,LVEDV,SPAP,KCCQ score,cardiothoracic ratio,Heart rate,BMI,Cr,and NYHA grade were better in case grou P than that in control grou P(P<0.05).Conclusions: 1.Sacubitril valsartan could significantly increase patient’s LVEF,and reduce the cardiac structural indicators such as LAD,LVEDD,LVESD,LVEDV,so as to improve the cardiac function of patients.2.Sacubitril valsartan could significantly reduce the pro-fibrotic factors SST2 and TIMP-1,reverse myocardial remodeling in patients with chronic heart failure,improve patients’ prognosis.3.Sacubitril valsartan could significantly improve the KCCQ score,improve patients’ NYHA grade,and improve the quality of life and activity tolerance of patients with chronic heart failure.